Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 13/20 | 0.46 |
| ▸ | MTOR | P42345 | 4/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1561230 | 1.00 | PDE4B (0.46) | PDE4BMTORPIK3CACDK4CDK2 | |
| SCHEMBL1560575 | 1.00 | PDE4B (0.46) | PDE4BMTORPIK3CACDK4CDK2 | |
| SCHEMBL1560593 | 1.00 | PDE4B (0.46) | PDE4BMTORPIK3CACDK4CDK2 | |
| SCHEMBL1560738 | 1.00 | PDE4B (0.46) | PDE4BMTORPIK3CACDK4CDK2 | |
| Hydrochloric Acid SCHEMBL1561171 | 0.99 | PDE4B (0.45) | PDE4BMTORPIK3CACDK4CDK2 | |
| Bromide SCHEMBL1561638 | 0.99 | PDE4B (0.45) | PDE4BMTORPIK3CACDK4CDK2 | |
| Hydrochloric Acid SCHEMBL1561670 | 0.99 | PDE4B (0.45) | PDE4BMTORPIK3CACDK4CDK2 | |
| Phosphoric Acid SCHEMBL1561811 | 0.98 | PDE4B (0.44) | PDE4BMTORPIK3CACDK4CDK2 | |
| Succinic Acid SCHEMBL1561102 | 0.97 | PDE4B (0.44) | PDE4BMTORPIK3CACDK4CDK2 | |
| Trifluoroacetic Acid SCHEMBL1561761 | 0.96 | PDE4B (0.44) | PDE4BMTORPIK3CACDK4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046787-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2011-04-06 | — | — | EP | claimed |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-31 | — | — | US | claimed |
| US-8003663-B2 | N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide; phosphodiesterase inhibitor; antiinflammatory, antiallergenic agent; chronic obstructive pulmonary disease (COPD), asthma, or rhinitis | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003663-B2 | N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide; phosphodiesterase inhibitor; antiinflammatory, antiallergenic agent; chronic obstructive pulmonary disease (COPD), asthma, or rhinitis | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| US-8003663-B2 | N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl)(methyl)amino]octanoyl}amino)benzamide; phosphodiesterase inhibitor; antiinflammatory, antiallergenic agent; chronic obstructive pulmonary disease (COPD), asthma, or rhinitis | GLAXO GROUP LIMITED (GB) | 2011-08-23 | — | — | US | disclosed |
| EP-2046787-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2011-04-06 | — | — | EP | disclosed |
| EP-2046787-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LTD (GB) | 2011-04-06 | — | — | EP | disclosed |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-31 | — | — | US | disclosed |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-31 | — | — | US | disclosed |
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2009-12-31 | — | — | US | disclosed |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | GLAXO GROUP LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| WO-2008015416-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325952-A1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4B, PDE4A, PDE12 | PDE4B 1/4885MTOR 1697/4885PIK3CA 769/4885 |
| US-20080058369-A1 | Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors | PDE4A, PDE4B, PDE3B | PDE4B 2/4885MTOR 2464/4885PIK3CA 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.